U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H25N3O4S
Molecular Weight 427.5185
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MORICIZINE

SMILES

CCOC(=Nc1ccc2c(c1)N(c3ccccc3S2)C(=O)CCN4CCOCC4)O

InChI

InChIKey=FUBVWMNBEHXPSU-UHFFFAOYSA-N
InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)

HIDE SMILES / InChI
Moricizine is an antiarrhythmic agent previously marketed as Ethmozine. It was used for prophylaxis and treatment of serious and life-threatening ventricular arrhythmias. In 2007 it was withdrawn and discontinued for commercial reasons. Moricizine can be administered intravenously but was more commonly provided as an oral formulation.

CNS Activity

Curator's Comment:: referenced study was conducted on guinea pig

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ETHMOZINE

Approved Use

Moricizine is used to correct irregular or rapid heartbeats to a normal rhythm. It is typically prescribed at a dose range of 600 - 900 mg/day, taken as 3 doses every 8 hours.

Launch Date

6.457536E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.597 mg/L
300 mg 3 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.607 mg/L
150 mg 3 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.6 mg/L
250 mg 3 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.666 mg/L
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.993 mg × h/L
300 mg 3 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.138 mg × h/L
150 mg 3 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.21 mg × h/L
250 mg 3 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.21 mg × h/L
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
300 mg 3 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.5 h
150 mg 3 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.4 h
250 mg 3 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.4 h
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MORICIZINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Disc. AE: Electrocardiogram change, Congestive heart failure...
AEs leading to
discontinuation/dose reduction:
Electrocardiogram change (17 patients)
Congestive heart failure (11 patient)
Atrial fibrillation (4 patients)
Nausea (34 patients)
Gastrointestinal upset (3 patients)
Anxiety (3 patients)
Hypoesthesia (2 patients)
Tremor of hands (2 patients)
Dyspnea (2 patients)
Urinary retention (4 patients)
Laboratory test abnormality (5 patients)
Drug fever (3 patients)
Blurred vision (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Congestive heart failure 11 patient
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Electrocardiogram change 17 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Dyspnea 2 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Hypoesthesia 2 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Tremor of hands 2 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Anxiety 3 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Blurred vision 3 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Drug fever 3 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Gastrointestinal upset 3 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Nausea 34 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Atrial fibrillation 4 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Urinary retention 4 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
Laboratory test abnormality 5 patients
Disc. AE
900 mg 1 times / day steady, oral
Recommended
Dose: 900 mg, 1 times / day
Route: oral
Route: steady
Dose: 900 mg, 1 times / day
Sources:
unhealthy, adult
n = 1256
Health Status: unhealthy
Condition: arrhythmias
Age Group: adult
Sex: M+F
Population Size: 1256
Sources:
PubMed

PubMed

TitleDatePubMed
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
1992 Jul
Exercise induced fatal sinusoidal ventricular tachycardia secondary to moricizine.
1992 Oct
Proarrhythmia in patients treated with moricizine.
1992 Sep
Action of MgSO4 differs from moricizine and verapamil on ouabain-induced ventricular tachycardia in normomagnesemic conscious dogs.
1994 Feb
[Mechanisms of action of hypersodium medium on contractile activity of isolated rat heart].
2001
Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A.
2002 Dec
Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block.
2002 Mar
Moricizine induced increase in pacing threshold.
2003 Jan
[Moricizine in treatment of one case with tachycardia-induced cardiomyopathy].
2003 Oct
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Patents

Sample Use Guides

Patients with greater than or equal to 30 ventricular premature complexes (VPCs) per hour were given moricizine HCL (816 +/- 103 mg daily) as a three times oral daily dose. Moricizine suppressed 81% of VPCs alone and 87% of VPCs in combination with 120 mg of propranolol.
Route of Administration: Oral
In Vitro Use Guide
Single ventricular myocytes from guinea-pig hearts were prepared by enzymatic dissociation. Isolated single cells were transferred to a recording chamber of an inverted phase-contrast microscope which was maintained at 34 - 35 deg-C. Membrane currents were recorded by using whole-cell patch-clamp technique using an amplifier. Application of 1O micro-M moricizine was started at 7 minutes and continued up to 13 minutes after the formation of whole cell configuration. In the absence of drug, the current decayed with time and the average value of relative currents at 20 min was 0.48 ± 0.11. In the presence of 10 micro-M moricizine, the tail currents decreased progressively with time and the minimum value of 0.29 was reached at 13 min after rupture of the membrane (or 6 min after the application of moricizine).
Name Type Language
MORICIZINE
MI   USAN   VANDF  
USAN  
Official Name English
EN-313 FREE BASE
Code English
MORACIZINE [INN]
Common Name English
MORICIZINE [VANDF]
Common Name English
MORICIZINE [MI]
Common Name English
MORACIZINE [WHO-DD]
Common Name English
MORACIZINE [MART.]
Common Name English
ETHYL 10-(3-MORPHOLINOPROPIONYL)PHENOTHIAZINE-2-CARBAMATE
Common Name English
MORACIZINE
INN   MART.   WHO-DD  
INN  
Official Name English
MORICIZINE [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175426
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
NCI_THESAURUS C47793
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
WHO-VATC QC01BG01
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
WHO-ATC C01BG01
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
250-854-5
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
MERCK INDEX
M7624
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY Merck Index
RXCUI
40169
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY RxNorm
CAS
31883-05-3
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
PUBCHEM
34633
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
IUPHAR
7244
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
INN
2998
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
FDA UNII
2GT1D0TMX1
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
DRUG CENTRAL
1842
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
MESH
D016293
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
EVMPD
SUB09062MIG
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
EPA CompTox
31883-05-3
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
DRUG BANK
DB00680
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
NCI_THESAURUS
C66196
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
WIKIPEDIA
MORACIZINE
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY
ChEMBL
CHEMBL1075
Created by admin on Sat Jun 26 13:12:31 UTC 2021 , Edited by admin on Sat Jun 26 13:12:31 UTC 2021
PRIMARY